Table 1.
Patient and tumor characteristics
| Characteristics | |
|---|---|
| No. of patients | 109 |
| Median age, years (range) | 56 (25‐84) |
| Disease stage, n = 109 (%) a | |
| Stage 0 | 12 (11%) |
| Stage I | 45 (41%) |
| Stage II | 29 (27%) |
| Stage III | 7 (6%) |
| Metastatic or recurrent disease | 16 (15%) |
| Subtype, n = 109 (%) | |
| ER+/PR+‐/HER2‐ | 90 (83%) |
| ER+‐/PR+‐/HER2+ | 7 (6%) |
| ER‐/PR‐/HER2‐ | 12 (11%) |
| Histology, n = 107 (%) b | |
| Invasive ductal carcinoma | 90 (84%) |
| Ductal in situ carcinoma | 12 (11%) |
| Others | 5 (5%) |
| Lymph node status, n = 98 (%) c | |
| Node positive | 31 (32%) |
| Node negative | 67 (68%) |
| Tumor size, n = 98 (%) c | |
| Tis | 12 (12%) |
| T1 | 55 (56%) |
| T2 | 22.4 (23%) |
| T3 | 3 (3%) |
| T4 | 6 (6%) |
| Metastases status, n = 107 (%)d | |
| M0 | 93 (87%) |
| M1 | 14 (13%) |
a
In patients with bilateral breast cancer, cancer with a higher stage was used for the analyses.
b
Tumor histological subtype not counted for 2 patients (P147, P174; refer Table S1) with bilateral breast cancer presenting different histological subtypes.
c
Tumor and lymph node stage data unavailable for some metastatic breast cancer patients.
d
Metastases status evaluation excludes recurrent disease patients (P49, P278; refer Table S1).